SBC Medical Group’s Q4 Revenue Drops to $39.6M; Analyst Holds $9 Target
Emerging Growth Research maintained its Buy-Extended rating on SBC Medical Group Holdings with a $9.00 price target after Q4:25 revenue of $39.6 million and improved operating income from last year. The company holds $164 million cash, operates 283 clinics with 6.6 million annual visits and expects revenue growth in 2026.
1. Analyst Update and Rating
Emerging Growth Research reiterated its Buy-Extended rating on SBC Medical Group Holdings, maintaining a $9.00 12-month price target. The update follows a quarterly review that considered recent financial results and ongoing strategic adjustments.
2. Q4 Financial Performance
In Q4:25, SBC recorded revenue of $39.6 million, down year-over-year due to franchise fee structure changes implemented in 2025. Despite lower revenue, operating income and net income rose significantly as prior-period non-recurring charges did not recur.
3. Balance Sheet Strength and Operations
The company holds approximately $164 million in cash with minimal debt, supporting operational flexibility and potential acquisitions. SBC’s network expanded to 283 clinics, serving 6.6 million annual visits with a repeat customer rate of 72%.
4. Outlook and Growth Strategy
Management projects revenue stabilization and modest growth in 2026, driven by operational efficiency initiatives, international expansion and new AI-driven and longevity-focused services. The firm’s strong cash position underpins selective M&A and long-term value creation strategies.